Asabys Partners, member of CataloniaBio & HealthTech, has led a Series A financing round of 14 million euros and Gradient Denervation Technologies has announced the closing of this round. The aim of this round is to support the clinical development and evaluation of the ultrasound-based ablation catheter through the new Sabadell Asabys II fund. 

Thuja Capital and early-stage investor Sofinnova Partners have also participated in leading the funding round. Gradient was established in 2020 through a seed financing from Sofinnova MD Start, the venture capital firm's MedTech accelerator. 

“Gradient’s technology has the potential to become a first-in-class treatment for patients suffering from heart failure and elevated pulmonary pressures. The company is ready to prove the concept of its technology in the clinic, and we look forward to joining the management in this exciting journey.", Sylvain Sachot, Asabys Partner.

“I’m very happy to welcome Asabys Partners and Thuja Capital to the Gradient team. In addition to capital, these investors bring deep expertise and thought partnership to Gradient as we seek to bring our technology to patients.”, Martin Grasse, CEO of Gradient. 

Asabys Partners is a venture capital firm specialized in the healthcare sector, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, participated by Alantra and with the support of Banc Sabadell as anchor investor. With close to €217 million in AUM and 15 portfolio companies (+1 exit), Asabys invests in highly innovative and disruptive companies covering unmet medical needs in the biopharma and healthtech verticals. The firm’s investment in the company comes from its vehicles Sabadell Asabys Health Innovation Investments II, FCR and Sabadell Asabys Health Innovation Investments 2B, SCR SA. This operation benefits from the support of the European Union under the InvestEU Fund.